Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 2/20 | 0.60 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4086021 | 0.92 | MAPK8 (0.59) | PTGER4MAPK8HPGDGAALMNA | |
| SCHEMBL4081701 | 0.92 | MAPK8 (0.64) | PTGER4MAPK8HPGDLMNASMN1; SMN2 | |
| SCHEMBL6458967 | 0.91 | PTGER4 (0.54) | PTGER4MAPK8HPGDGAALMNA | |
| SCHEMBL4087178 | 0.88 | MAPK8 (0.69) | PTGER4MAPK8HPGDLMNASMN1; SMN2 | |
| SCHEMBL7317640 | 0.88 | MAPK8 (0.75) | PTGER4MAPK8HPGDLMNASMN1; SMN2 | |
| SCHEMBL4085475 | 0.87 | MAPK8 (0.62) | PTGER4MAPK8HPGDLMNASMN1; SMN2 | |
| SCHEMBL7168843 | 0.86 | MAPK8 (0.72) | PTGER4MAPK8GAA | |
| SCHEMBL7371983 | 0.86 | MAPK8 (0.69) | PTGER4MAPK8HPGDLMNASMN1; SMN2 | |
| SCHEMBL4455558 | 0.85 | MAPK8 (0.62) | PTGER4MAPK8HPGDLMNASMN1; SMN2 | |
| SCHEMBL4087209 | 0.85 | PTGER4 (0.58) | PTGER4MAPK8HPGDLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | JUNG BIRGIT | 2009-01-15 | — | — | US | claimed |
| US-20050154006-A1 | Pharmaceutical compositions based on a scopineester and nicotinamide derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | claimed |
| US-20050043343-A1 | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-24 | — | — | US | claimed |
| US-20050026886-A1 | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-03 | — | — | US | claimed |
| US-6756392-B2 | CARBOCYCLIC SECONDARY AMIDES SUCH AS 2-(4-FLUORO-PHENOXY) -N-(4-((2-HYDROXY-3-METHYL-BENZOYL AMINO)-METHYL)-BENZYL)-NICOTINAMIDE, ADMINISTERED FOR PROPHYLAXIS OF RESPIRATORY SYSTEM DISORDERS | PFIZER INC | 2004-06-29 | — | — | US | claimed |
| US-20030195233-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | MAGEE THOMAS V (US) | 2003-10-16 | — | — | US | claimed |
| US-20030191158-A1 | Antiinflamamtory agents; antiallergens | PFIZER INC. | 2003-10-09 | — | — | US | claimed |
| EP-2116245-A2 | EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | disclosed |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | JUNG BIRGIT | 2009-01-15 | — | — | US | disclosed |
| US-20050154006-A1 | Pharmaceutical compositions based on a scopineester and nicotinamide derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-07-14 | — | — | US | disclosed |
| US-20050043343-A1 | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-24 | — | — | US | disclosed |
| US-20050026886-A1 | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-02-03 | — | — | US | disclosed |
| US-6756392-B2 | CARBOCYCLIC SECONDARY AMIDES SUCH AS 2-(4-FLUORO-PHENOXY) -N-(4-((2-HYDROXY-3-METHYL-BENZOYL AMINO)-METHYL)-BENZYL)-NICOTINAMIDE, ADMINISTERED FOR PROPHYLAXIS OF RESPIRATORY SYSTEM DISORDERS | PFIZER INC | 2004-06-29 | — | — | US | disclosed |
| US-20030195233-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | MAGEE THOMAS V (US) | 2003-10-16 | — | — | US | disclosed |
| US-20030191158-A1 | Antiinflamamtory agents; antiallergens | PFIZER INC. | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026886-A1 | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor | PDE12, PDE3A, PDE3B | PTGER4 198/4885MAPK8 4158/4885HPGD 464/4885 |
| US-20030195233-A1 | Nicotinamide derivatives useful as PDE4 inhibitors | PDE4A, PDE4B, PDE4C | PTGER4 49/4885MAPK8 1524/4885HPGD 32/4885 |
| US-20030191158-A1 | Antiinflamamtory agents; antiallergens | NNMT, IL5, HNMT | PTGER4 290/4885MAPK8 4288/4885HPGD 64/4885 |
| US-20090017036-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF RESPIRATORY AND GASTROINTESTINAL DISORDERS | BDKRB2, EDNRB, GRK5 | PTGER4 76/4885MAPK8 88/4885HPGD 888/4885 |
| US-20050043343-A1 | Medicaments for inhalation comprising an anticholinergic and a PDE IV inhibitor | PDE3A, PDE4B, PDE12 | PTGER4 230/4885MAPK8 3666/4885HPGD 663/4885 |
| US-20050154006-A1 | Pharmaceutical compositions based on a scopineester and nicotinamide derivatives | NAMPT, NNT, XDH | PTGER4 1543/4885MAPK8 2628/4885HPGD 98/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.